A critical review of Alberta Stroke Program Early CT Score for evaluation of acute stroke imaging
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Are Peptides Difficult to Detect
The letter warned that injectable products can pose risks of serious harm and gave the company 15 working days to respond
IVF and Pregnancy Outcomes: The Triumphs, Challenges, and Unanswered Questions
Substantial weight loss may create a temporary discrepancy between the internal body self and the changed physical appearance, a phenomenon described in qualitative and psychodynamic work as ghost fat or identity lag [70, 71]
